Clinical updates for colon cancer care in 2022
JC Fabregas, B Ramnaraign, TJ George - Clinical colorectal cancer, 2022 - Elsevier
Colon cancer needs better screening and treatment options. Its incidence in the young
population is rising. Recent changes in guidelines recommend beginning screening for …
population is rising. Recent changes in guidelines recommend beginning screening for …
Impact of diabetes and metformin use on recurrence and outcome in stage II–III colon cancer patients—a pooled analysis of three adjuvant trials
N Christou, ES Bergen, C Canton, K Le Malicot… - European Journal of …, 2022 - Elsevier
Background Diabetes mellitus (DM) has been associated with increased colorectal cancer
(CRC) risk and worse prognosis in metastatic CRC patients. In this large, pooled analysis of …
(CRC) risk and worse prognosis in metastatic CRC patients. In this large, pooled analysis of …
[HTML][HTML] G-CSF filgrastim biosimilar-Sandoz reduces the incidence of febrile neutropenia in patients receiving chemotherapy regimens with rest periods not exceeding …
JM Phelip, PJ Souquet, M Hacini, M Chehimi… - Cancer Treatment and …, 2023 - Elsevier
Purpose The objective of this study was to describe filgrastim biosimilar-Sandoz modalities
of use in patients receiving cytotoxic chemotherapy regimens with a rest period of≤ 14 days …
of use in patients receiving cytotoxic chemotherapy regimens with a rest period of≤ 14 days …
Maintenance therapy with Fluoropyrimidine and cetuximab or bevacizumab after first line FOLFOX-chemotherapy in metastatic colorectal cancer according to RAS or …
S Kang, MW Lee, IC Song, HJ Lee, HJ Yun… - Journal of Cancer …, 2023 - Springer
Purpose Fluoropyrimidine (FP) with oxaliplatin-based chemotherapy is the standard first-line
treatment for metastatic colorectal cancer (mCRC); however, oxaliplatin-induced neuropathy …
treatment for metastatic colorectal cancer (mCRC); however, oxaliplatin-induced neuropathy …
Patterns of patient-reported chemotherapy-induced peripheral neuropathy in colorectal cancer survivors
C Teng, PL Blinman, JL Vardy - Journal of the National Comprehensive …, 2022 - jnccn.org
Background: Chemotherapy-induced peripheral neuropathy (CIPN) can be a debilitating
toxicity of oxaliplatin used for treatment of colorectal cancer (CRC). We aimed to assess …
toxicity of oxaliplatin used for treatment of colorectal cancer (CRC). We aimed to assess …
Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor …
Z Chakrani, G Mellgard, N Saffran… - American Journal of …, 2024 - journals.lww.com
Objectives: Androgen receptor–targeted therapies (ARTs) improve survival outcomes in
patients with metastatic castration-resistant prostate cancer (mCRPC); however, a significant …
patients with metastatic castration-resistant prostate cancer (mCRPC); however, a significant …
Early Age Onset Colorectal Cancer: A Canadian Perspective
MJ Raphael - Canadian Oncology Today, 2024 - canadianoncologytoday.com
In Canada, 92% of colorectal cancer cases occur in patients over 50 years of age.
Accordingly, most colorectal cancer research and early-detection efforts have traditionally …
Accordingly, most colorectal cancer research and early-detection efforts have traditionally …
Using National Routine Data to Explore the Utilisation and Outcomes of Multimodal Treatment in the Management of Colorectal Cancer
GM Boyle - 2022 - researchonline.lshtm.ac.uk
Background: The multimodal treatment of colorectal cancer (CRC) is becoming
progressively more complex with multidisciplinary input required to make appropriate …
progressively more complex with multidisciplinary input required to make appropriate …
Quels critères de choix et quel schéma de chimiothérapie adjuvante après résection d'un cancer colique?
▼ Abstract After surgery with curative intent, the decision for adjuvant treatment in patients
with stage II and III colon cancer (CC) is based on several factors: the patient's eligibility or …
with stage II and III colon cancer (CC) is based on several factors: the patient's eligibility or …
Which selection criteria and which adjuvant chemotherapy regimen after resection of colon cancer?
▼ Abstract After surgery with curative intent, the decision for adjuvant treatment in patients
with stage II and III colon cancer (CC) is based on several factors: the patient's eligibility or …
with stage II and III colon cancer (CC) is based on several factors: the patient's eligibility or …